In addition, ZEB2 would be a novel therapeutic target for pathogenic diseases involving fibrosis, including liver cirrhosis, cardiac fibrosis, pulmonary fibrosis and scleroderma. Here, ZEB2 is linked to pulmonary fibrosis.